As of today (2024-06-01), ContraFect's share price is $0.015.
ContraFect's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-23.67. Hence, ContraFect's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for ContraFect's Price-to-Free-Cash-Flow or its related term are showing as below:
CFRXQ's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.975 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 27.30% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 28.40% per year.
During the past 11 years, ContraFect's highest 3-Year average Free Cash Flow per Share Growth Rate was 35.90% per year. The lowest was 13.50% per year. And the median was 30.85% per year.
ContraFect Price-to-Free-Cash-Flow Historical Data
The historical data trend for ContraFect's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ContraFect's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, ContraFect's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContraFect's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ContraFect's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ContraFect's Price-to-Free-Cash-Flow falls into.
ContraFect Price-to-Free-Cash-Flow Calculation
ContraFect's Price-to-Free-Cash-Flow ratio for today is calculated as
ContraFect's Share Price of today is $0.015. ContraFect's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
ContraFect Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of ContraFect's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CFRXQ has been successfully added to your 